Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE. This study was to compare HAIC with FOLFOX with sorafenib who showed TACE-resistant.

Inclusion Criteria:

• Diagnosed with HCC according to the European Association for the Study of the Liver (EASL) diagnostic criteria
• TACE failure/refractoriness by Liver Cancer Study Group of Japan (LCSGJ) criteria
• Without extrahepatic metastasis
• The following laboratory parameters:

Platelet count ≥ 60,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) >1,500/mm3

Exclusion Criteria:

• Known history of HIV
• History of organ allograft
• Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
• Serious non-healing wound, ulcer, or bone fracture
• Evidence of bleeding diathesis.
• Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug